1. Show article details.

    Teva, Allergan Settle Opioid Lawsuit With West Virginia

    Benzinga – 3:55 PM ET 05/25/2022

    Teva, Allergan Settle Opioid Lawsuit With West Virginia

  2. Show article details.

    US Raises Objection To Johnson & Johnson's High Cost Lawyer For Talc Bankruptcy Case: Reuters

    Benzinga – 12:25 PM ET 05/25/2022

    US Raises Objection To Johnson & Johnson's High Cost Lawyer For Talc Bankruptcy Case: Reuters

  3. Show article details.

    Teva, Allergan reach $161.5 mln opioid settlement with West Virginia

    Reuters – 12:23 PM ET 05/25/2022

    Teva Pharmaceutical Industries and AbbVie's Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said on Wednesday.

  4. Show article details.

    Fortune 500 List Includes Cryptocurrency Company For The First Time; 30 Return After Missing 2021

    Benzinga – 9:56 AM ET 05/25/2022

    Fortune released its annual Fortune 500 list, ranking the largest companies in America by revenue. Cryptocurrency Earns Its Place: For the first time ever, a cryptocurrency company landed on the Fortune 500 List. A company needed to have 2021 revenue of $6.4 billion to enter the list, a mark that was up 19% from the previous year's list.

  5. Show article details.

    CNBC's Final Trades: O'Reilly Automotive, Best Buy, JPMorgan Chase And This 'Top-Notch' Pharma Stock

    Benzinga – 8:30 AM ET 05/25/2022

    On CNBC's "Halftime Report Final Trades," Stephanie Link of Hightower chose Johnson & Johnson, saying that it's "a top-notch pharmaceutical business." She added, "Medical device is recovering as we reopen, and you have the consumer spin early next year." Rob Sechan of New Edge Capital Group said his firm had owned O'Reilly Automotive Inc for "a long time."

  6. Show article details.

    French health body backs new COVID vaccine booster campaign for this autumn

    Reuters – 6:03 AM ET 05/25/2022

    France's Haute Autorite de Sante health authority recommended preparing for a new vaccination campaign this autumn to give people aged 65 and older, and those with special health risks or conditions, access to a COVID-19 "booster" jab. The French government typically follows the recommendations of the country's health authority body.

  7. Show article details.

    BRIEF-Janssen Presents Study Results Showing Clinical Efficacy For Tremfya® (Guselkumab) And Long-Term Safety Profile For Stelara® (Ustekinumab) For Patients Living With Inflammatory Bowel Disease At Digestive Disease Week® 2022

    Reuters – 4:44 PM ET 05/24/2022

    Janssen Pharmaceutical Companies: * JANSSEN PRESENTS STUDY RESULTS SHOWING CLINICAL EFFICACY FOR TREMFYA® AND LONG-TERM SAFETY PROFILE FOR STELARA® FOR PATIENTS LIVING WITH INFLAMMATORY BOWEL DISEASE AT DIGESTIVE DISEASE WEEK® 2022. * JANSSEN - OTHER DATA PRESENTED DEMONSTRATE LONG-TERM SAFETY PROFILE OF STELARA® IN BIO-NAÏVE & BIO-FAILURE PATIENTS LIVING WITH INFLAMMATORY BOWEL DISEASE.

  8. Show article details.

    Nigeria receives 4.4 million doses of J&J COVID vaccine from Spain

    Reuters – 1:52 PM ET 05/24/2022

    Nigeria has received 4.4 million doses of the Johnson & Johnson COVID-19 vaccine from Spain, a government official said on Tuesday.

  9. Show article details.

    9 Stocks Moved By Traders On 'Fast Money: Halftime Report'

    Benzinga – 1:26 PM ET 05/24/2022

    CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. Citigroup Inc - Shares climbed 0.27% higher after Market Rebellion's Pete Najarian said he bought call options in the company's stock.

  10. Show article details.

    BRIEF-FDA Grants Breakthrough Device Designation To Anumana's ECG Pulmonary Hypertension Early Detection AI Algorithm

    Reuters – 8:20 AM ET 05/24/2022

    Anumana Inc: * FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO ANUMANA'S ECG PULMONARY HYPERTENSION EARLY DETECTION AI ALGORITHM Source text for Eikon: Further company coverage:

  11. Show article details.

    FOCUS-U.S. Task Force to consider routine kidney disease screening as new drugs available

    Reuters – 6:22 PM ET 05/23/2022

    An influential U.S. panel has added screening for chronic kidney disease to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier.

  12. Show article details.

    Amid Monkeypox Outbreak, This 3X Leveraged ETF Provides Exposure To Health Sector: What To Watch

    Benzinga – 12:31 PM ET 05/23/2022

    The Direxion Daily Healthcare Bull 3X Shares gapped up almost 2.52% higher on Monday in response to outbreaks of monkeypox being reported in several western nations. CURE is a triple leveraged fund that is designed to outperform 72 U.S. companies in the home health care sector.

  13. Show article details.

    BRIEF-New Data From Two Large Studies Reinforce Effectiveness Of Dual Pathway Inhibition With Xarelto Plus Aspirin In Patients With CAD And/Or PAD

    Reuters – 9:13 AM ET 05/23/2022

    Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ): * NEW DATA FROM TWO LARGE STUDIES REINFORCE EFFECTIVENESS OF DUAL PATHWAY INHIBITION WITH XARELTO PLUS ASPIRIN IN PATIENTS WITH CAD AND/OR PAD Source text for Eikon: Further company coverage:

  14. Show article details.

    U.S. Task Force to consider routine kidney disease screening as new drugs available

    Reuters – 7:16 AM ET 05/23/2022

    -An influential U.S. panel has added screening for chronic kidney disease to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier.

  15. Show article details.

    FOCUS-U.S. Task Force to consider routine kidney disease screening

    Reuters – 7:00 AM ET 05/23/2022

    An influential U.S. panel has added screening for chronic kidney disease to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier.

  16. Show article details.

    The Trials And Tribulations Of Psychedelic Research

    Benzinga – 1:00 PM ET 05/20/2022

    Microdose and appears here with permission. A growing body of research into the therapeutic use of psychedelics, including -- MDMA, psilocybin, LSD, ketamine, and DMT, are delivering promising results to treat a wide range of conditions such as post-traumatic stress disorder, depression, end-of-life anxiety, eating disorders, stroke, and chronic pain.

  17. Show article details.

    ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug

    Benzinga – 10:19 AM ET 05/20/2022

    ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug

  18. Show article details.

    Vaccination after infection may curb long COVID; desktop 'air curtains' may deflect virus particles

    Reuters – 4:03 PM ET 05/19/2022

    - The following is a summary of some recent studies on COVID-19. Post-infection vaccination may reduce long COVID. Vaccination after infection with SARS-CoV-2 may contribute to a reduction in the burden of long COVID symptoms, a new study suggests.

  19. Show article details.

    COVID SCIENCE-Vaccination after infection may curb long COVID; desktop 'air curtains' may deflect virus particles

    Reuters – 3:59 PM ET 05/19/2022

    The following is a summary of some recent studies on COVID-19. Post-infection vaccination may reduce long COVID. Vaccination after infection with SARS-CoV-2 may contribute to a reduction in the burden of long COVID symptoms, a new study suggests.

  20. Show article details.

    What Are Whales Doing With Johnson & Johnson

    Benzinga – 12:02 PM ET 05/19/2022

    Someone with a lot of money to spend has taken a bullish stance on Johnson & Johnson. And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know. So how do we know what this whale just did?

Page:

Today's and Upcoming Events

  • Jul
    19

    JNJ to announce Q2 earnings (Confirmed)

Past Events (last 90 days)

  • May
    23

    JNJ ex-Dividend for $1.13 on 05/23/2022

    • Announce Date: 04/19/2022
    • Record Date: 05/24/2022
    • Pay Date: 06/07/2022
  • Apr
    19

    JNJ announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.